|Pre-clinical||Phase i/ii||Phase iii||NDA/MAA|
GI & Inflammation
|RHB-105||H. pylori infections|
|Gastroenteritis & gastritis|
Oncology - GI/Inflammation
|YELIVA™ (ABC294640)||Multiple indications|
RedHill Biopharma (NASDAQ / TASE: RDHL) is an emerging Israeli biopharmaceutical company focused primarily on the development and acquisition of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of inflammatory and gastrointestinal diseases, including gastrointestinal cancers.
RedHill Board of Directors and team wish to express their deepest sadness over the passing of our very dear friend, Alicia Rotbard, a member of RedHill’s Board of Directors. Our thoughts and prayers are with her family and many loved ones. She will be greatly missed.